-- Company Management and Directors Establish Stock Purchase Plans --
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 18, 2014--
(NASDAQ: OVAS), a global life sciences company focused on the discovery,
development and commercialization of new fertility treatments, announced
today that the underwriters of its previously announced public offering
of common stock have exercised their option to purchase an additional
518,630 shares of common stock at the public offering price of $10.00
per share. As a result, total gross proceeds to OvaScience from this
offering are $55.2 million before deducting the underwriting discounts,
commissions and estimated expenses.
Leerink Partners LLC acted as the sole book-running manager of the
public offering. Co-Managers included Cantor Fitzgerald & Co., H.C.
Wainwright & Co., LLC, JMP Securities LLC, Ladenburg Thalmann & Co., and
Roth Capital Partners.
Separately, the Company’s CEO, Michelle Dipp, M.D., Ph.D., Chairman of
the Board, Richard Aldrich, and Board member Harald Stock, Ph.D. have
set up 10b5-1 plans to purchase OvaScience common stock in the open
market. The plans allow for the acquisition by these individuals of
predetermined amounts of securities on a non-discretionary basis. The
details of the transactions will be available publicly through Form 4
filings with the Securities and Exchange Commission.
The public offering of common stock was made pursuant to a shelf
registration statement on Form S-3 that was filed with the Securities
and Exchange Commission (“SEC”). A preliminary and final prospectus
supplement and accompanying base prospectus relating to the offering has
been filed with the SEC. Copies of the final prospectus supplement and
accompanying prospectus may be obtained from Leerink Partners LLC,
Attention: Syndicate Department, One Federal Street, 37th
Floor, Boston, MA, 02110, or by phone at 1-800-808-7525, ext. 4814, or
by email at Syndicate@leerink.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or jurisdiction in which such an offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
OvaScience (NASDAQ: OVAS) is a global life sciences company focused on
the discovery, development and commercialization of new fertility
Theresa McNeely, 617-299-7356